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Amino acid uptake in the intestine and kidney 
is mediated by a variety of amino acid 
transporters. To understand the role of 
epithelial neutral amino acid uptake in whole 
body homeostasis we analyzed mice lacking 
the apical broad-spectrum neutral (0) amino 
acid transporter B0AT1 (Slc6a19). A general 
neutral aminoaciduria was observed similar 
to human Hartnup disorder, which is caused 
by mutations in SLC6A19. Na+-dependent 
uptake of neutral amino acids into the 
intestine and renal brush-border membrane 
vesicles was abolished. No compensatory 
increase of peptide transport or other neutral 
amino acid transporters was detected. Mice 
lacking B0AT1 showed a reduced body 
weight. When adapted to a standard 20% 
protein diet, B0AT1 deficient mice lost body 
weight rapidly on diets containing 6% or 
40% protein. Secretion of insulin in response 
to food ingestion after fasting was blunted. In 
the intestine, amino acid signalling to the 
mammalian target of rapamycin (mTOR) 
pathway was reduced, while the GCN2/ATF4 
stress response pathway was activated, 
indicating amino acid deprivation in 
epithelial cells. The results demonstrate that 
epithelial amino acid uptake is essential for 
optimal growth and body weight regulation. 
INTRODUCTION 
In a typical Western diet humans consume about 
80-100 g of protein per day. Proteins are 
hydrolyzed by the action of secreted and 
membrane-bound peptidases into individual 
amino acids, di- and tri-peptides (1). Individual 
amino acids are taken up by a variety of amino 
acid transporters, while di- and tri peptides are 
absorbed by the peptide transporter PepT1 
(SLC15A1) (2). Together this digestive process 
makes 90-95% of ingested proteins available to 
the body. Protein demand is particularly high 
during growth and development when new 
proteins are required to build up body mass. In 
the adult, protein recycling is quite efficient and 
only 50 g of protein is needed per day to replace 
protein lost through urine and faeces. 
The bulk of neutral amino acids are absorbed in 
the intestine by the neutral amino acid 
transporter B0AT1 (SLC6A19), which is also 
expressed in the kidney where it mediates 
reabsorption of neutral amino acids (3). 
Expression studies in heterologous systems have 
shown that B0AT1 accepts all neutral amino 
acids with a preference for large neutral amino 
acids such as branched-chain amino acids and 
methionine (4,5). These amino acids are taken 
up with a KM of about 1 mM, while smaller 
amino acids are taken up with higher KM-values. 
Glycine and proline are poor substrates of 
B0AT1. As a result additional transporters are 
involved in the uptake of imino acids and 
glycine, such as PAT1 (SLC36A1), PAT2 
(SLC36A2) and IMINO (SLC6A20) (6). 
Additional transport systems for other neutral 
amino acids in the kidney and intestine have 
been proposed, these include a specific intestinal 
transporter for methionine and phenylalanine (7) 
and the amino acid antiporter ASCT2 (SLC1A5) 
as a mediator of small neutral amino acids and 
glutamine uptake in kidney and intestine (8). 
Efficient trafficking and surface expression of 
B0AT1 at the apical membrane of the kidney and 
intestine requires coexpression of the type-I 
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membrane protein homologs collectrin 
(TMEM27) (9) or angiotensin-converting 
enzyme 2 (ACE2) (10), respectively. In the 
absence of these auxiliary proteins, B0AT1 
remains sequestered within intracellular 
compartments. 
Reduced uptake of neutral amino acids is 
observed in the rare inherited malabsorption 
syndrome Hartnup disorder (11). Hartnup 
disorder is characterized by highly elevated 
levels of neutral amino acids in the urine and 
reduced neutral amino acid uptake in the 
intestine. In some individuals, clinical symptoms 
such as skin rash, cerebellar ataxia, and 
psychotic behavior are observed. Furthermore, 
individuals with Hartnup disorder tend to be of 
smaller stature, although the significance of 
these data are limited due to the small number of 
clinically evaluable cases (12). In 2004, we and 
others showed that Hartnup disorder is caused 
by mutations in SLC6A19 (13,14). The 
frequency of one SLC6A19 allele (D173N) was 
surprisingly common in the normal population 
(13). Mice lacking collectrin (Tmem27) have a 
similar renal phenotype as humans with Hartnup 
disorder, but lack the intestinal phenotype (9). 
Ace2 nullizygous mice have a more complex 
phenotype including cardiac deficiencies and 
glomerulosclerosis, but exhibit normal urine 
amino acid levels (15,16). 
A number of questions remain unanswered from 
studies of Hartnup disorder and intestinal amino 
acid transport. Firstly, what is the significance of 
amino acid transport for protein nutrition relative 
to peptide transport in the intestine? Secondly, is 
B0AT1 the only neutral amino acid transporter in 
the intestine? Lastly, what is the basis of the 
clinical symptoms observed in Hartnup 
disorder? 
In order to address these questions, we have 
examined a variety of physiological and 
pathological parameters in a new Slc6a19 
nullizygous mouse model to gain further insights 
into amino acid transport in the intestine and 
kidney. The results suggest that B0AT1 is the 
major neutral amino acid transporter in the 
intestine and that the absence of B0AT1 reduces 
growth, impairs body weight control and insulin 
response. 
 
EXPERIMENTAL PROCEDURES 
Slc6a19 nullizygous mice 
Slc6a19 nullizygous mice were purchased on the 
129 background under license from Deltagen 
(San Mateo, California, USA). The mice were 
generated from embryonic stem cells in which 
exon 3 of Slc6a19 was targeted by homologous 
recombination by replacing nucleotides 438-466 
(RefSeq NM_028878) by a LacZ-Neo (βgeo) 
cassette (Figure 1A). Slc6a19 heterozygous mice 
were then backcrossed onto the inbred 
C57BL/6J strain for at least 4 generations (N4). 
In most experiments N4 nullizygous mice were 
compared to wildtype littermates. Where 
indicated, nullizygous mice backcrossed for 8 
generations (N8) were used for phenotypic 
analysis and compared to heterozygous and 
homozygous littermates. The genotype of the 
mice was confirmed in two independent 
laboratories using different sets of primers as 
listed in Supplemental Table 2. Genotyping for 
nicotinamide nucleotide transhydrogenase was 
performed as described (17). All animal 
breeding and experimentation was performed 
according to institutional guidelines for the care 
and use of experimental animals (ANU 
F.BMB.35.07 and CI K75-9-2009-3-512). Any 
blood samples were removed by retroorbital 
bleeding and animals were sacrificed by cervical 
dislocation or CO2 asphyxiation. 
Transport studies 
Radiolabeled amino acids were purchased from 
GE Healthcare or MP Biomedicals. The 
following compounds were used: L-
[3H]carnosine, [U-14C]glycine, D-[U-
14C]glucose, D-[1,3-3H]glucose, L-[U-
14C]glutamate, L-[U-14C]glutamine, L-[G-
3H]glutamine, L-[U-14C]histidine, L-[U-
14C]leucine, L-[3,4,5-3H]leucine, L-[U-
14C]proline, L-[2,3,4,5-3H]proline, L-[5-
3H]tryptophan. Usually tritium-labeled 
compounds were used when a high-specific 
activity was required (e.g. vesicle experiments), 
otherwise [14C]-labeled compounds were used. 
Brush-border membrane vesicles (BBMV) from 
kidney were prepared following the protocol of 
Biber et al. (18). Kidney BBMV were used for 
transport studies when the alkaline phosphatase 
activity was more than 15-fold enriched in the 
BBMV compared to homogenate. Vesicles were 
preloaded with K+ by incubation for 30 min in 
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93mM K2SO4, 10 mM MES-Tris pH 7.5 at 
25°C. Subsequently, vesicles were centrifuged at 
48,000g for 30 min and were resuspended at a 
concentration of 2-4 µg/µl in mannitol buffer 
(280 mM mannitol, 10 mM MES-Tris pH 7.5). 
The concentrated vesicles (20 µl) were energized 
for 1 min at 37°C by addition of valinomycin at 
a final concentration of 100 µg/ml. 
Subsequently, 80 µl of transport buffer was 
added to this mixture, resulting in a final 
concentration of 100 µM of radiolabeled 
substrate (for [14C]-labeled substrates 0.3 µCi 
carrier-free compound was added; for [3H]-
labeled substrates 0.5 µCi carrier-free compound 
was added). Two types of transport buffer were 
used: a Na+-containing buffer (100 mM NaCl, 
80 mM mannitol, 10 mM MES-Tris pH 7.5) and 
a Na+-free buffer (280 mM mannitol, 10 mM 
MES-Tris pH 7.5). For amino acid transport the 
overshoot peak was determined after 15 s and 
the equilibrium time point was taken after 5 min. 
The choice of the equilibrium time point was 
based on the observation that vesicles appeared 
to bind labeled amino acids non-specifically 
when the equilibrium value was measured after 
30 or 60 min. 
To prepare intestinal vesicles, animals were 
sacrificed and all three sections (duodenum, 
jejunum and ileum) of the small intestine were 
quickly removed and placed in ice-cold storage 
solution (0.9% NaCl, 1 mM glutamine, 
“complete” protease inhibitor, EDTA-free 
(Roche Diagnostics) 1 tablet per 50 ml). Using a 
syringe, the intestine was rinsed with the storage 
solution to remove any faeces and inverted by 
sliding it over a metal rod. The inverted intestine 
was placed in a petri-dish containing ice-cold 
300 mM mannitol, 5 mM EGTA, 12 mM Tris 
pH 7.4 solution containing 2 mM glutamine or 2 
mM glucose and protease inhibitor. Mucosal 
cells were removed by scraping the intestine 
with a microscope slide. Subsequently, BBMV 
were prepared as described by Biber et al. (18). 
BBMV from intestine showed little transport 
activity and therefore inverted sections of small 
intestine were used for transport studies. The 
inverted intestine was prepared as described 
above and placed in a petri-dish containing 
Hank’s buffered salt solution (136.6 mM NaCl; 
5.4 mM KCl; 0.44 mM KH2PO4; 2.7 mM 
Na2HPO4; 1.26 mM CaCl2; 0.5 mM MgCl2; 0.4 
mM MgSO4; 10 mM HEPES pH 7.4)  containing 
2 mM glutamine or glucose and protease 
inhibitor. For transport measurements, the 
intestine was cut into 1 cm pieces before sliding 
it onto plastic stirring rods. The rods were placed 
in 5 ml γ-counter tubes containing 2 ml of 
Hank’s buffer, 100 µM unlabeled and 5 µCi 
carrier-free labeled substrate. For transport in 
Na+-free conditions, NaCl was replaced by 
choline-Cl and Na2HPO4 was replaced by 
K2HPO4. All transport experiments were 
performed at 37°C. 
Immunofluorescence 
Kidney and intestinal samples were fixed in 10% 
neutral buffered formalin for at least 24 h. 
Subsequently, specimens were dehydrated by 
sequential changes of 80%, 95% then 100% 
ethanol, followed by washes in xylene. 
Dehydrated tissues were then embedded in 
paraffin, sectioned using a microtome and 
placed on poly-L-lysine coated slides. Prior to 
staining, the slides were de-paraffinised through 
sequential 10 min immersions in Histoclear 
(GeneWorks, Hindmarsh, SA, Australia), 95% 
ethanol and 100% ethanol, followed by two 10 
min washes in PBS and two 5 min washes in 
triple distilled water. De-paraffinised slides were 
immersed in 600 ml of 0.1 M citrate buffer (pH 
6.0) which was maintained at a rolling boil for 
15 min. Submerged slides were further 
incubated in the cooling buffer for 20 min before 
washing twice in PBS. Tissues were outlined 
with a Pap Pen (Invitrogen, Mount Waverley, 
Vic, Australia) before applying 200 µl of 20% 
BlokHen II™ (Aves Laboratories, Tigard, OR, 
U.S.A) in PBS to each section. The primary 
antibodies were applied to the sections and 
binding was detected with fluorochrome-
conjugated secondary antibodies. Both 
antibodies were applied for 30 minutes each at 
37oC in a humidified incubation chamber. All 
reagents were diluted in PBS according to 
Supplemental Table 1. Following each 
incubation, the slides were washed three times in 
PBS to remove any unbound antibodies. Finally, 
sections were mounted in ProLong Gold anti-
fade reagent (Invitrogen, Mount Waverley, Vic, 
Australia) to preserve the fluorescence of the 
section and set overnight before visualisation. 
Digital images were obtained using the 40x or 
60x oil objective with a LAS-AF system 
installed on a Leica TSC SP5 confocal 
microscope using the lasers according to the 
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fluorochrome used. As a control, sections were 
stained with secondary antibody only. Images 
were, if necessary, processed using Adobe 
Photoshop CS3 Extended Version 10.0.1 (Adobe 
Systems, San Jose, CA, USA) to enhance 
contrast. Images of controls and treated slices 
were processed with the same settings. 
SDS-PAGE and Western blotting 
Protein samples were separated by SDS-PAGE 
and blotted onto nitrocellulose membranes by 
electrophoretic transfer. After blocking non-
specific binding sites, proteins were probed 
using antibody dilutions as listed in 
Supplemental Table 1, before being detected by 
enhanced chemiluminescence (ECL system, GE 
Healthcare). 
Histology 
To compare the intestinal morphology of 
Slc6a19 nullizygous and wildtype (C57Bl/6J) 
mice, three adult male mice of each genotype 
were sacrificed before segments of jejunum and 
ileum were harvested.  Tissues were fixed in 
10% neutral buffered formalin for subsequent 
paraffin embedding and sectioning at 6 µm 
thickness. Slides were then de-paraffinised 
through sequential 10 min immersions in 
Histoclear (GeneWorks, Australia), 95% ethanol 
and 100% ethanol before incubating in Harris 
hematoxylin (Fronine, Australia) for 40 min to 
stain cell nuclei. After rinsing for 2 min each in 
deionised water and Scott’s Blueing Solution 
(Sigma Aldrich, MO, U.S.A.), the slides were 
briefly dipped in 80% ethanol before incubating 
in alcoholic Eosin-Y solution containing 0.1% 
phloxine (Fronine) for 10 min. The slides were 
then rapidly dehydrated in graded changes of 
alcohol and Histoclear, mounted in DPX 
(Sigma-Aldrich) and viewed on a Leica MZ 
FLIII fluorescence stereomicroscope (Leica 
Microsystems, Switzerland). 
Urine amino acid analysis 
Mice were held for 24 h in metabolic cages to 
collect urine. Urine samples (50 µl) were treated 
with 50 units of urease (50 µl) at 37°C for 30 
min. Subsequently samples were cleared by 
centrifugation and 300 µl methanol and 15 µl 
ribitol (2mg/ml) was added. Samples were 
mixed and dried in a speed vac. Methoximation 
of carbonyl groups was performed by the 
addition of 20 µl methoxylamine-HCl to the dry 
samples followed by incubation for 90 min at 
37°C. Trimethylsilyl (TMS) esters were then 
created by the addition of 40 µl N-trimethylsilyl-
N-methyltrifluoroacetamide was added and the 
samples incubated for a further 30 min at 30°C.  
For the gas chromatography-mass spectrometry 
(GC-MS) analysis, samples were injected as 1 µl 
derivatized metabolites in a 20:1 split ratio. The 
GC-MS equipment consisted of an Agilent 7680 
autosampler, an Agilent 7890 gas 
chromatograph and an Agilent 5975 N 
quadrupole mass spectrometer (Agilent, Palo 
Alto, CA, USA). The GC-MS system was auto-
tuned using perflurotributylamine. A 30 m 
Varian VF-5 ms column with a 10 m integrated 
Varian EZ-Guard column was used for the gas 
chromatography (Varian, Palo Alto, CA, USA). 
Injection temperature was 230°C, interface 
temperature was 300°C and the ion source 
temperature was 230°C. The temperature 
gradient consisted of an initial temperature of 
70°C increasing 15°C per min to a final 
temperature of 300°C. Mass spectra and 
chromatograms were normalized to the ribitol 
internal standard and processed using 
AnalyzerPro (SpectralWorks Ltd, Runcorn, 
U.K.) employing the MatrixAnalyzer function.  
Amino acid signalling and insulin 
determination 
The small intestine was removed, inverted as 
described for the transport assay and placed in 
Hank’s buffered salt solution. The sections were 
incubated in 50 mM leucine for 30 min at 37°C. 
This concentration is similar to the total 
concentration of amino acids in the lumen of the 
intestine after a meal (1).  Subsequently, two 
sections of 1cm each were homogenised in 1ml 
RIPA buffer (100 mM Tris-HCl (pH 7.5), 150 
mM NaCl, 1 mM EDTA, 1% Triton X-100, 
0.5% sodium deoxycholate, 0.1% SDS) 
supplemented with “complete” protease inhibitor 
(Roche Diagnostics, Mannheim, Germany). The 
homogenates were centrifuged at 10,000g for 10 
min and a volume of the clear supernatant 
containing 100 µg protein used as a sample for 
SDS-PAGE. Proteins were detected as described 
under SDS-PAGE and Western blotting.   
To determine the insulin response, mice were 
fasted for 12-16 h, and 20-50 µl of blood was 
collected before and 60 mins after addition of 
pre-moistened chow into the cage. Glucose 
levels were measured using a calibrated blood 
glucose meter (Accu-Chek). Plasma insulin 
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levels were determined by an enzyme-linked 
immunosorbent assay (ELISA) specific for 
mouse insulin (Alpco diagnostics, Salem, NH, 
USA).  
Mouse body weight and diet experiments 
Mice body weight experiments were performed 
with litters from female Slc6a19 heterozygous 
founders crossed with male Slc6a19 wildtype, 
heterozygous or nullizygous founders to reduce 
any variation in maternal nutritional 
supplementation. All mice were weighed every 
2- 3 days. Genotype and gender was determined 
at day 22.  For diet experiments animals were 
fed ad libitum with either low, normal, or high 
protein diet (6%, 20%, or 40% protein 
respectively) for at least 11 days, with one to 
three animals per cage. Weights of live mice 
were measured at least every second day using a 
fine scale. For measuring diet-induced changes 
in lean and fat tissue contribution to total weight, 
mice were anesthetized and placed in a Lunar 
PIXImus Densitometer (GE Medical Systems, 
USA), and each mouse was subjected to 3 
measurements both before and after change of 
diet.  
Expression of Slc6a19 
Pancreas tissue was immediately placed in lysis 
buffer (Nucleospin RNA II, Macherey-Nagel, 
Germany) and homogenised. Slc6a19 mRNA 
was detected after reverse transcription by 26 
cycles of PCR using primers as listed in 
Supplementary Table 2. 
Statistical analysis 
All transport experiments were performed three 
times and representative samples are shown in 
the figures. The number of mice used for each 
experiment is stated in the figure legends. When 
comparing parametric data from two groups the 
unpaired t-test was used. When comparing more 
than two groups ANOVA combined with 
Student-Newman-Keuls multiple comparison 
test was used. The chi-square test was used to 
compare expected versus experimental data. 
Probability values for differences to occur by 
chance are indicated as * at p <0.05, ** at p 
<0.01, *** at p < 0.001. 
RESULTS 
The Slc6a19 nullizygous mouse was generated 
from embryonic stem cells targeted by 
homologous recombination (Deltagen, San 
Mateo, CA, USA) to replace nucleotides 438-
466 (Ref sequence NM_028878) in Slc6a19 
exon 3 by a LacZ-Neo cassette (Figure 1A). The 
presence of wildtype or targeted mutant Slc6a19 
alleles was verified by PCR (Figure 1B) and the 
lack of B0AT1 protein in brush-border 
membrane vesicles (BBMV) from kidney and 
intestine was confirmed by SDS-PAGE and 
Western blotting (Figure 1C). The ratio of 
wildtype, heterozygous and homozygous 
littermates from Slc6a19 heterozygous founders 
was consistent with inheritance of a Mendelian 
trait. The numbers of each genotype from a 
sample of 88 animals were wildtype 21, 
heterozygous 42 and homozygous 25, which is 
not significantly different from the expected 
ratio of 22:44:22 (χ2 test P = 0.878). This 
suggested that the absence of Slc6a19 does not 
affect the viability of the growing embryo. 
We detected B0AT1 protein by 
immunofluorescence in both kidney and 
intestine of wild-type mice (Figure 2), as we and 
others have reported recently (10,19,20). In 
wild-type kidney expression of B0AT1 was co-
localized with the proximal tubule marker Lotus 
tetragonolobus agglutinin (LTA) on the apical 
membranes of proximal tubular epithelial cells 
(Figure 2A). In the intestine, B0AT1 was 
detected in the apical membrane of enterocytes, 
with expression increasing towards mature 
enterocytes at the tip of the villus (Figure 2B). 
No immunofluorescence was detected in kidneys 
of Slc6a19 nullizygous mice (Figure 2C), while 
in the intestine a weak non-specific staining was 
observed (Figure 2D). To investigate whether 
absence of B0AT1 had any consequences on the 
anatomical structure of the intestine, we 
performed histological analyses of hematoxylin- 
and eosin-stained organs from Slc6a19 
nullizygous and wildtype mice. Blinded 
examination (J.E.J.R) revealed no difference in 
the morphology of intestine samples from 
Slc6a19 nullizygous mice compared to those 
from wildtype mice (data not shown). 
The hallmark of Hartnup disorder is an increased 
excretion of neutral amino acids with the urine 
due to reduced reabsorption. To verify that 
Slc6a19 nullizygous mice display the same 
aminoaciduria as humans, we analyzed urinary 
amino acids by GC-MS. Amino acids were 
below the detection limit in the urine of wildtype 
mice, whereas large amounts of neutral amino 
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acids, such as alanine, asparagine, glycine, 
glutamine, isoleucine, methionine, phenylalanine 
serine, threonine, and tyrosine were observed in 
the urine of Slc6a19 nullizygous mice (Figure 
3A), consistent with the human Hartnup disorder 
phenotype. Due to the derivatization method 
employed, glutamate and the majority of 
glutamine were converted into pyroglutamate 
and could not be discriminated, while tryptophan 
cannot be detected by this method. 
Transport experiments were performed to 
evaluate the role of B0AT1 in neutral amino acid 
uptake in kidney and intestine. In mouse renal 
BBMV isolated from wildtype mice, leucine 
uptake showed a Na+-dependent overshoot 
(maximal at 15 s), indicating an active transport 
process (Figure 3B). Imposition of a K+-
diffusion potential using valinomycin in vesicles 
preloaded with potassium further increased 
leucine uptake, indicating an electrogenic 
transport process. These characteristics of Na+-
dependent leucine uptake into renal BBMV were 
consistent with the properties of system B0 as 
described in earlier studies and with the 
transport properties of the B0AT1 transporter 
(4,21,22). For all subsequent figures the 15 s 
time point is presented after subtraction of non-
specifically bound radiolabel. The Na+-
dependent leucine uptake observed in wildtype 
renal BBMV (Figure 4A) was absent in Slc6a19 
nullizygous mice. The small amount of Na+-
independent leucine transport observed in both 
animal groups may reflect a contamination of 
the BBMV with fragments of basolateral 
membrane. Glutamate uptake, which is largely 
mediated by Slc1a1 (EAAT3/EAAC1) (23,24), 
was similar in both groups of mice. Surprisingly, 
glucose transport was reduced by more than 
50% in the Slc6a19 nullizygous mice. 
Tryptophan deficiency due to lack of transport is 
thought to play a crucial role in the development 
of clinical symptoms in Hartnup disorder (25). 
Tryptophan transport in wildtype renal BBMV 
was largely Na+-dependent. Both, the Na+-
dependent and the Na+-independent component 
of tryptophan uptake were absent in Slc6a19 
nullizygous mice (Figure 4A). Glutamine and 
histidine uptake were also almost entirely Na+-
dependent in wildtype mice, but Slc6a19 
nullizygous mice showed residual transport 
activity for both amino acids (Figure 4A). The 
remaining Na+-dependent glutamine transport 
activity in Slc6a19 nullizygous mice was 
partially inhibited by histidine, threonine and to 
a lesser extent by leucine and the amino acid 
analogue N-methylaminoisobutyric acid 
(MeAib) (Figure 4B). Vice versa, histidine 
uptake was also partially inhibited by glutamine 
and MeAib (Figure 4B). To evaluate whether the 
residual activity for both amino acids was 
mediated by the same carrier, we challenged 
uptake of 100 µM [3H]glutamine or 100 µM 
[14C]histidine with 50 mM unlabelled glutamine 
or histidine (Figure 4C). This excess of 
unlabeled substrate reduced both glutamine and 
histidine uptake by almost 70%, whereas Na+-
independent glutamine transport was completely 
abolished (Figure 4C). The Na+-dependent 
glutamine transporter ASCT2 (Slc1a5) has been 
reported to be involved in glutamine uptake in 
the kidney (8). Because ASCT2 is an amino acid 
antiporter, its activity is only visible in BBMV 
when preloaded with glutamine as an antiport 
substrate. No stimulation of Na+-dependent 
glutamine uptake in vesicles derived from 
wildtype and Slc6a19 nullizygous mice was 
observed under these conditions, refuting the 
presence of ASCT2 activity. Only the Na+-
independent glutamine uptake was significantly 
increased (Figure 4D). To further evaluate the 
presence of ASCT2 in proximal tubules, we 
performed SDS-PAGE and Western blotting 
with renal BBMV proteins, using brain tissue as 
a positive control (Figure 5A). In brain tissue 
extract two bands were detected with molecular 
masses of approximately 55 kDa and 100 kDa, 
consistent with the detection of a monomer 
(calculated mass 58 kDa) and dimer of the 
transporter. Both bands disappeared when the 
antibody was preincubated with the 
immunogenic peptide (Figure 5B). Whilst two 
bands corresponding to ASCT2 were detected in 
kidney, neither of these was enriched in BBMV, 
suggesting that ASCT2 is not expressed in the 
apical membrane of the proximal tubule in mice. 
Similarly, we observed weak ASCT2-like 
immunoreactivity in homogenates from small 
intestine, which was also not enriched in 
BBMV, suggesting expression of ASCT2 
outside the apical membrane or epithelial cells 
(Figure 5C). 
Renal dipeptide uptake was assayed using the 
PepT2 (Slc15a2) substrate carnosine (β-alanyl-
histidine, Figure 4A). Carnosine uptake in 
kidney BBMV was Na+-independent and 
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appeared to be slightly reduced in Slc6a19 
nullizygous mice. However, its uptake was small 
compared to leucine uptake at the same 
concentration (100 µM). 
Transport experiments with renal BBMV 
revealed that B0AT1 also mediates a substantial 
part of proline and glycine transport (Figure 5D). 
Glycine uptake, which was largely Na+-
dependent, was reduced by approximately 60% 
in Slc6a19 nullizygous mice. Glycine uptake in 
both animal groups was inhibited by leucine, 
suggesting the presence of a second neutral 
amino acid transporter. Proline uptake was 
reduced by about 50% in Slc6a19 nullizygous 
mice. The remaining activity was Na+-dependent 
and sensitive to inhibition by MeAib, but not by 
glycine, suggesting that it was mediated by the 
IMINO transporter (Slc6a20a). 
Overall, the results demonstrate that B0AT1 is 
the major neutral amino acid transporter in the 
kidney. Additional transport activities were 
found for glutamine/histidine, proline and 
glycine. 
Intestinal vesicles, despite containing large 
amounts of B0AT1 protein (see Figure 1C), 
showed a very low transport activity. As a result 
we used inverted intestine to study transport in 
this tissue. For transport experiments, randomly 
selected 1 cm long sections of the complete 
small intestine were used since no obvious 
gradient of transport activity was observed along 
the small intestine (Figure 5E). Leucine uptake 
in inverted sections of the small intestine was 
largely Na+-dependent, but the residual Na+-
independent transport in the intestine was greater 
than in kidney BBMV (Figure 5E and 6A). The 
Na+-dependent leucine uptake was reduced by 
approximately 50% in heterozygous animals (p 
< 0.05) and disappeared completely in Slc6a19 
nullizygous mice (Figure 6A). In contrast, the 
Na+-independent component remained largely 
unchanged in all genotypes. This component 
was partially inhibited by arginine, suggesting 
that it was mediated in part by the heterodimeric 
cationic amino acid transporter rBAT/b0,+AT 
(Slc3a1/Slc7a9) (Figure 6B). Similar to the 
kidney, the lack of B0AT1 also had an effect on 
intestinal glucose uptake, which was reduced by 
approximately 40% in Slc6a19 nullizygous mice 
(p < 0.01; Figure 6C). To explain this finding, 
we considered the possibility that the apical 
glucose transporter SGLT1 (Slc5a1) may form a 
complex with B0AT1. Consistent with this idea, 
coexpression of B0AT1, ACE2 and SGLT1 in 
oocytes increased the activity of SGLT1 (Figure  
6D). 
Na+-dependent glutamine, histidine and 
tryptophan uptake was completely absent in 
Slc6a19 nullizygous mice (Figure 6E) as well, 
indicating that active uptake of neutral amino 
acids in the intestine is mediated entirely by 
B0AT1. Leucine and glucose uptake were 
repeated in this panel for comparison. Dipeptide 
uptake, measured as carnosine transport was 
largely Na+-independent, consistent with it being 
mediated by the proton-coupled peptide 
transporter PepT1 (Figure 6F). The transport 
activity was similar in all three genotypes. Since 
peptide uptake was not upregulated in Slc6a19 
nullizygous mice, we investigated whether the 
expression of other neutral amino acid 
transporters were altered in response to the lack 
of B0AT1. SDS-PAGE and Western blotting of 
BBMV proteins from small intestine and kidney 
suggested that neither of the two related neutral 
amino acid transporters B0AT2 (Slc6a15) or 
B0AT3 (Slc6a18) was upregulated in Slc6a19 
nullizygous mice (Figure 7). Moreover, no 
compensatory changes were observed for  
collectrin and ACE2, which are required for 
surface expression of B0AT1 in the kidney and 
in the intestine, respectively (10).  
For human adults a daily protein intake of 0.8 
g/kg body weight is recommended (26). Amino 
acids, particularly glutamine, are used as energy 
substrates as well as to build up tissue mass. 
Skeletal muscle is the main storage organ for 
amino acids in the body. We hypothesized that 
the absence of B0AT1 could have an impact on 
body mass. Consistent with this hypothesis, 
Slc6a19 nullizygous mice appeared to be smaller 
in body size compared to heterozygous and 
wildtype mice (Figure 8 A, C). Body weight 
measurements of female and male groups of 
each genotype throughout postnatal development 
showed that Slc6a19 nullizygous mice had a 
lower body weight than heterozygous and wild-
type litter mates (Figure 8 B, D). Prior to 
weaning and gender-determination, which 
occurred at approximately 22 days post-birth, 
both homozygous, heterozygous and wildtype 
mice exhibited a similar rate of growth, 
regardless of gender (Figure 8 B, D). All litters 
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were weaned from heterozygous Slc6a19 
mothers to reduce any variation in maternal 
nutritional supplementation. However, post-
weaning, the growth curves for male (Figure 8B) 
and female (Figure 8D) homozygous mice 
diverged from their heterozygous and wildtype 
littermates. By 12 weeks of age, male and 
female Slc6a19 nullizygous mice weighed 
approximately 17% and 14% less, respectively, 
than gender-matched adult wildtype mice. The 
experiment was performed with both N4 and N8 
(shown in the figure) mice compared to litter 
mates, both giving the same conclusion. 
The change of body weight became more 
dramatic when mice were fed with diets of 
different protein composition. After reaching 
adulthood, mice of all genotypes maintained a 
relatively constant body weight on a standard 
20% protein chow. However, Slc6a19 
nullizygous mice rapidly lost weight on a 6% 
protein diet, while wild-type mice maintained a 
constant body weight (Figure 9A). Heavier 
Slc6a19 nullizygous mice tended to lose more 
weight (up to 25%) than lighter mice, even when 
analyzed on a percentage scale (Figure 9B). 
Upon resumption of the normal diet (20% 
protein), Slc6a19 nullizygous mice regained 
weight within 8 days, some even compensating 
above their pre-diet weight (Figure 9C). 
Surprisingly, the Slc6a19 nullizygous mice also 
lost weight, when placed on a 40% protein diet, 
while wildtype mice remained constant or even 
gained some weight (Figure 9D). The weight 
recovery took longer when the mice were 
returned from a 40% diet onto 20% protein diet 
(Figure 9E), and fluctuations of body weight 
were observed during recovery (Figure 9E 
inset). Together these results demonstrate that 
efficient absorption of amino acids in the 
intestine is critical for the control of body 
weight. 
To analyze which components of the body 
changed during these experiments we measured 
body fat and water content using X-ray-based 
densitometry. These data indicate that on a 6% 
protein diet, the Slc6a19 nullizygous mice 
mainly lost lean tissue (consisting mainly of 
muscle), while on a 40% diet they lost both lean 
tissue and fat (Figure 10). Wildtype mice 
exhibited only a small loss in lean tissue on the 
6% diet, with smaller weight changes on both 
20% and 40% diets. In addition they showed 
more variability in fat content than Slc6a19 
nullizygous mice. 
Amino acids are known to activate signaling via 
the mTOR pathway, thereby increasing protein 
translation. A lack of amino acids is sensed by 
the GCN2-ATF4 stress response pathway 
leading to a reduction of general protein 
synthesis (27). To investigate whether deletion 
of Slc6a19 results in altered mTOR signaling in 
the intestine, we measured the levels of total and 
phosphorylated S6 protein (Rps6 and p-Rps6). 
Similarly, we measured the levels of total and 
phosphorylated eIF2α - indicating the activity of 
the GCN2-ATF4 pathway. The total levels of 
Rps6 were similar in wildtype and Slc6a19 
nullizygous mice (Figure 11). However, p-Rps6 
was generally lower in Slc6a19 nullizygous 
mice, suggesting reduced signaling by the 
mTOR pathway due to the lack of amino acid 
uptake. Consistent with this, we observed a 
small increase in the phosphorylation of eIF2α, 
suggesting that the absence of B0AT1 causes 
amino acid deprivation in epithelial cells. 
Paracellular transport is a significant route for 
ion and water transport in the intestine and may 
also provide an alternative route for amino acid 
absorption. Permeability of tight junctions is 
controlled by claudins and occludins (28). In 
order to investigate whether lack of B0AT1 had 
an impact on tight junction permeability, we 
measured the amount of the tight-junction 
markers claudin-2 (Cldn2) and occludin (Ocln) 
by SDS-PAGE Western blotting (Figure 11). 
Both markers were significantly reduced in 
Slc6a19 nullizygous mice suggesting that lack of 
the transporter has a significant impact on 
epithelial permeability.  
Amino acid uptake during digestion and 
absorption of foods leads to signaling processes 
not only in the intestine, but also in other organs. 
The response of plasma insulin to the feeding-
fasting cycle was blunted in Slc6a19 nullizygous 
mice (Figure 12A). After 16h fasting, plasma 
insulin levels were higher in Slc6a19 
nullizygous mice than in wildtype mice, while 
1h after refeeding insulin levels were lower in 
the Slc6a19 nullizygous animals than in 
wildtype animals (Figure 12A). Consistent with 
an effect of B0AT1 activity on insulin secretion, 
we could detect Slc6a19 mRNA in extracts of 
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wildtype mouse pancreas, but not in Slc6a19 
nullizygous mice (Figure 12B). 
DISCUSSION 
In this study we demonstrate that Slc6a19 
nullizygous mice provide more than just a model 
of human Hartnup disorder. The mice offer 
insights into amino acid transport in kidney and 
intestine as well as signaling processes generated 
by nutritional protein. Neutral aminoaciduria, 
the most reliable Hartnup disorder phenotype, is 
reproduced in these mice. In humans, additional 
clinical symptoms are sometimes observed in 
young individuals, such as a skin rash, cerebellar 
ataxia and psychotic behaviour (25). We have 
not observed any signs of ataxia even when 
Slc6a19 nullizygous mice were held on a 6% 
protein diet, which resulted in significant weight 
loss. Some Slc6a19 nullizygous develop 
dermatitis, however, the numbers were too small 
for further analysis.  
A putative mouse model for Hartnup disorder 
has been generated previously using random 
mutagenesis by N-ethyl-N-nitrosourea, 
combined with screening by urine amino acid 
analysis (29). Surprisingly, the mutated locus in 
this mouse model was located within 0.8 cM of 
the fibroblast growth factor 3 gene on 
chromosome 7 (30). This locus is not close to 
Slc6a19 (chr. 13), Tmem27 or Ace2 (both chr. 
X), moreover there are no obvious candidate 
genes in this interval. As a result, the 
aminoaciduria observed in this strain remains 
unexplained. 
The transport studies demonstrate a surprisingly 
simple picture of neutral amino acid transport in 
the intestine (Figure 13). It appears that B0AT1 
is the only active neutral amino acid transporter 
for leucine, glutamine, histidine and tryptophan. 
The ASCT2 transporter has previously been 
suggested to mediate a significant part of 
glutamine uptake in both intestine and kidney 
(8,31). However, due to its Na+-dependence and 
substrate specificity, ASCT2 activity can be 
confused with that of B0AT1. Glutamine is one 
of the preferred substrates of ASCT2, and the 
complete absence of Na+-dependent glutamine 
uptake in intestinal sections of Slc6a19 
nullizygous mice suggests that ASCT2 does not 
participate in glutamine uptake in this tissue. 
Nevertheless, immunofluorescence studies have 
suggested the presence of ASCT2 in the apical 
membrane of rabbit small intestine (8). By 
contrast, we did not detect ASCT2-like 
immunoreactivity in intestinal BBMV. Together 
these findings show that in mouse intestine 
neutral amino acids are mainly transported by 
B0AT1. In addition, we detected significant Na+-
independent uptake of neutral amino acids, 
which appears to reflect a non-productive neutral 
amino acid exchange via the heterodimeric 
amino acid transporter rbat/b0,+AT. 
Physiologically, this transporter exchanges 
luminal cationic amino acids against cytosolic 
neutral amino acids (32) and can thus be 
inhibited by neutral amino acids. In addition 
paracellular uptake could contribute to Na+-
independent uptake of neutral amino acids. 
Alternatively, neutral amino acids can be 
absorbed as di- or tripeptides (33). Uptake of the 
PepT1 substrate carnosine (34) was lower than 
leucine uptake, suggesting that amino acid 
uptake via B0AT1 has a similar or even higher 
capacity than peptide uptake via PepT1 
(Slc15a1) at a substrate concentration of 100 
µM. There was no compensatory increase of 
peptide uptake in Slc6a19 nullizygous mice. A 
recent analysis of Slc15a1 nullizygous mice 
supports the view that amino acid uptake is more 
dominant than peptide uptake in the intestine (2). 
SLC15A1 nullizygous mice did not show 
reduced growth or body weight. However, 
PepT1 appeared to be relevant for absorption of 
high-protein loads. 
In mouse kidney, B0AT1 provides the main 
transport activity for neutral amino acids. Flux 
measurements suggested the additional presence 
of a Na+-dependent glutamine/histidine 
transporter, which was inhibited by MeAib and 
thus may reflect system A activity. Detailed 
immunofluorescence studies of system A 
transporters SNAT1 (SLC38A1) and SNAT2 
(SLC38A2) in the kidney have not been 
reported, but the transporters are expected to 
have a basolateral expression. ASCT2-like 
activity has been reconstituted from rat renal 
BBMV (35). However, we did not detect 
glutamine uptake in glutamine-preloaded BBMV 
from this tissue in mice and also could not detect 
ASCT2-like immunoreactivity in mouse renal 
BBMV. Thus in contrast to previous reports 
using rabbit and rat tissue (8,35) we conclude 
that there is no ASCT2-like activity in mouse 
renal BBMV. However, we cannot exclude 
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species differences with regard to amino acid 
transport. 
Due to the dominance of B0AT1 in neutral 
amino acid uptake, the complexity of glycine 
and proline transport has been difficult to 
evaluate (32). Recent studies from our 
laboratories provided evidence for the 
involvement of the proton-dependent glycine 
and proline transporter PAT2 (SLC36A2), the 
IMINO transporter (SLC6A20) and of the 
glycine/alanine transporter B0AT3 (SLC6A18) 
in renal tubular transport of these two amino 
acids (6,19). Glycine transport in both wildtype 
and Slc6a19 nullizygous mice was completely 
inhibited by leucine, pointing to another neutral 
amino acid transporter and at the same time 
excluding a significant role of PAT2. Thus, 
glycine transport is most likely mediated by 
B0AT1 and B0AT3. This is consistent with the 
glycinuria and minor neutral aminoaciduria 
displayed by Slc6a18 nullizygous mice (16,36), 
as well as the lack of inhibition of proline uptake 
by glycine observed in this study. The Na+-
dependence and MeAib sensitivity of proline 
uptake indicates that it was most likely mediated 
by the IMINO transporter (37). Thus, in contrast 
to humans, where the bulk of glycine uptake is 
mediated by PAT2 and B0AT1 (6), in mice it is 
likely to be mediated by B0AT1 and B0AT3. 
Consistent with this observation, we found in a 
previous study that humans lacking SLC6A18, 
do not show glycinuria (6). 
In addition to the insights gained into neutral 
amino acid uptake in kidney and intestine, this 
study represents the first demonstration that a 
lack of neutral amino acid uptake can cause 
significant changes in intracellular signaling 
processes and whole body homeostasis. The 
body weight and size of Slc6a19 nullizygous 
mice was reduced compared to wildtype mice, 
which is in agreement with anecdotal 
observations in humans (12). Furthermore, we 
observed that these mice not only have a lower 
body-weight but also have problems maintaining 
a constant body weight in response to diets of 
different protein content. Analysis of the 
different components of body mass in Slc6a19 
nullizygous mice suggested that a switch to diets 
containing either 6% or 40% protein resulted in 
loss of lean tissue mass (mainly muscle), but in 
addition there was a reduction of fat on the 40% 
protein diet. The 40% and 20% diets are 
isocaloric and as a result the 40% protein diet 
contains fewer carbohydrates. The loss of weight 
on the 40% protein diet may thus result from the 
reduced insulin response in the Slc6a19 
nullizygous mice, which would normally 
stimulate conversion of glucose into fat. In 
addition Slc6a19 nullizygous mice showed 
reduced glucose uptake. The insulin response in 
Slc6a19 nullizygous mice was blunted both 
during fasting and feeding, demonstrating that 
nutritional protein levels have a modulatory role 
of the insulin response. This is consistent with 
the observed role of glutamine in the release of 
insulin from pancreatic β-cells (38). We could 
detect B0AT1 mRNA in pancreas, but do not 
know whether it is expressed in β-cells, where 
the B0AT1 trafficking subunit collectrin has 
been found (39,40). It has been reported that 
some strains of C57Bl/6J mice have deletions in 
the nicotinamide nucleotide transhydrogenase 
(Nnt), resulting in a reduced insulin response 
(17). Genotyping of the mice used in this study 
showed that all mice had the complete genomic 
sequence of Nnt gene (data not shown). 
In addition we found that two key amino acid 
signaling pathways are altered in Slc6a19 
nullizygous mice. The ribosomal S6 protein 
showed reduced phosphorylation, suggesting 
that the mTOR pathway in intestinal cells does 
respond to amino acids absorbed through the 
apical membrane and that this response is 
reduced in Slc6a19 nullizygous mice. Thus, the 
lack of apical uptake is not compensated by 
increased uptake across the basolateral 
membrane. Consistent with this observation, we 
found increased amounts of phospho-eIF2α, 
which indicates amino acid starvation and results 
in reduced protein synthesis (27). The 
consequences of these changes in signaling are 
as yet unknown, however, we observed reduced 
amounts of the tight-junction proteins claudin-2 
and occludin, possibly allowing a higher level of 
paracellular amino acid transport to compensate 
for the lack of transcellular transport. 
Our characterisation of Slc6a19 nullizygous 
mice reveals that the major neutral amino acid 
transporter is an active regulator of amino acid 
signaling and whole body homeostasis. The 
B0AT1 transporter appears to be the major 
mechanism for neutral amino acid uptake in 
intestine and kidney.
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Footnotes 
Abbreviations: BBMV, Brush-border membrane vesicles; EGTA, ethylene glycol tetraacetic acid; 
ELISA, enzyme-linked immunosorbent assay, GC-MS, gaschromatography-mass spectrometry; MES, 
2-(N-morpholino)ethanesulfonic acid; MeAib, N-Methylaminisobutryic acid, TMS trimethylsilyl 
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FIGURE LEGENDS 
Figure 1: Confirmation of gene targeting in Slc6a19 nullizygous mice. 
(A) Schematic representation of the insertion of the LacZ-Neo cassette into exon 3 of the Slc6a19 
gene. (B) Genotype confirmation using PCR detecting the targeted allele (primer pair a and c, 485bp) 
or the wildtype allele (primer pair b and c, 201bp). (C) Expression of B0AT1 protein was detected by 
SDS-PAGE and Western blotting in BBMV derived from kidney (K) and small intestine (I). 
Genotypes (Slc6A19 wildtype (+/+), heterozygous (+/-) and nullizygous (-/-)) and molecular weights 
are indicated in the panel margins. 
 
Figure 2: Immunolocalization of B0AT1 in intestine and kidney. 
Expression of B0AT1 protein was detected in wildtype (A, B) and Slc6a19 nullizygous mice (C, D) 
by immunofluorescence (green) in the apical membrane of intestinal enterocytes (B, D) and in the 
early segments of the kidney proximal tubule (A, C). The arrow in panel (A) indicates the beginning 
of the proximal tubule next to a glomerulus (g). Apical staining in the proximal tubule was identified 
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by costaining with Lotus tetragonolobus lectin (red). The bars in the lower right corner indicate a 
distance of 10 µm. 
 
Figure 3: Urine amino acid analysis and transport assay in BBMV 
(A) Urine was collected for 24 h from each wildtype (+/+) and nullizygous (-/-) mice. In the samples 
amino acids were analysed by GC-MS and the peak areas were normalized to that of the internal 
control ribitol. The most abundant derivative for each amino acid is shown. TMS indicates 
derivatization with trimethylsilyl-residues, the number in brackets refers to the multiplicity of 
derivatization. The figure shows the mean ± SEM urine concentration of n=4 mice from each 
genotype, amino acids were below the detection limit in the wildtype samples. (B) Basic properties of 
leucine transport in mouse renal BBMV. Uptake of [14C]leucine (0.1 mM) was studied in renal 
BBMV derived from wildtype mice in the presence and absence of Na+. To establish an inside-
negative membrane potential, vesicles were preloaded with 93 mM K2SO4 and treated with 
valinomycin (Val, 1 µg/ml) before the uptake experiments. 
 
Figure 4: Nutrient uptake in kidney BBMV from wildtype and Slc6a19 nullizygous mice. 
(A) Uptake of radiolabeled nutrients (0.1 mM) was studied in renal BBMV derived from wildtype 
(+/+, black and hatched bars) and Slc6a19 nullizygous animals (-/-, grey and white bars) in the 
presence (black and grey bars) and absence (hatched and white bars) of Na+. (B, C) Glutamine and 
histidine uptake (0.1 mM) was measured in Slc6a19 nullizygous mice in the presence (grey bars) and 
absence (white bars) of Na+ and in the presence of 10 mM (B) or 50 mM (C) unlabeled amino acids or 
amino acid analogues. (D) To detect Na+-dependent antiport activity as carried out by ASCT2 
(Slc1a5) Na+-dependent and Na+-independent glutamine uptake was determined in vesicles that were 
preloaded with 20 mM glutamine for 30 min or remained in control buffer. For each experiment 
kidneys from at least 3 animals were pooled and each bar represents the mean ± SD of 3 vesicle 
samples. Significant differences between wildtype and Slc6a19 nullizygous mice are indicated in 
panel A and D and to the uninhibited controls in panel B and C. 
 
Figure 5: Detection of ASCT2 and transport in renal BBMV and sections of inverted intestine. 
Panel (A) SDS-PAGE and Western blotting was used to detect ASCT2 [(Slc1a5) calculated mass 58 
kDa monomer and 116 kDa dimer] in mouse kidney homogenate (K), BBMV and brain homogenate 
(Br). (B) Protein extracts were made from brain tissue (lane 1), oocyte plasma membranes expressing 
ASCT2 (lane 2) and non-injected oocytes (lane 3). After separation by SDS-PAGE, samples were 
blotted onto nitrocellulose and detected with ASCT2 antiserum (-). In the lower panel (+) the 
immunoreactivity was blocked by preincubation of the antiserum with the immunogenic peptide (2 
µg/ml). (C) Detection of ASCT2 by immunoblotting after separation of protein extracts from brain 
(Br), intestinal BBMV and intestinal tissue homogenate (I). (D) Proline and glycine uptake (0.1 mM) 
was measured in the presence and absence of Na+ and in the absence and presence of 10 mM 
unlabeled amino acids. Kidneys from at least 3 animals were pooled for each experiment and each bar 
represents the mean ± SD of 3 vesicle samples. Significant differences to uninhibited controls are 
indicated. (E) Leucine uptake activity in Na+-containing and Na+-free buffer was measured in 10 
randomly selected 1 cm long pieces of mouse small intestine, derived from 3 different mice and is 
depicted as a quartiled box-and-whisker plot. The Slc6a19 genotypes are indicated as +/+ and -/-. 
 
Figure 6: Nutrient uptake in mouse intestine. 
Sections of inverted intestine (1 cm) were incubated with radiolabeled substrates (0.1 mM) for 30 s at 
37°C. Subsequently, sections were washed three times in ice-cold transport buffer and the 
incorporated activity determined by scintillation counting. (A) Leucine uptake was measured in the 
presence and absence of Na+ in Slc6a19 wildtype (+/+), heterozygous (+/-) and nullizygous (-/-) 
intestines and (B) in the absence and presence of 10 mM arginine. (C) Glucose uptake was measured 
in the presence and absence of Na+ in wildtype, heterozygous and Slc6a19 nullizygous intestines. (D) 
Oocytes were injected with cRNA encoding SGLT1, B0AT1 and ACE2. Glucose uptake was 
measured for 20 min and the activity of non-injected control oocytes was subtracted in each case. (E) 
Na+-dependent uptake of radiolabelled nutrients (each 0.1 mM) was measured in sections of inverted 
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intestine derived from wildtype and Slc6a19 nullizygous mice. (F) Uptake of carnosine (0.1 mM) was 
measured in sections of inverted intestine derived from wildtype and slc6a19 nullizygous mice in the 
presence and absence of Na+. For each transport experiment sections from at least 3 animals were 
pooled and each bar represents the mean ± SD of 3 intestinal sections. Each experiment was 
performed at least three times with similar results. Statistical significance is indicated in relation to 
wildtype activity in panels A, B, C, E and F or to the control condition in D. 
 
Figure 7: Immunodetection of nutrient transporters and their ancillary proteins in mouse renal 
and intestinal brush-border membrane vesicles. 
BBMV were isolated from intestine (I) and kidney (K) derived from wildtype (+/+), heterozygous (+/-
) and Slc6a19 nullizygous (-/-) mice. Protein (30 µg) was separated by SDS-PAGE. Nutrient 
transporters and auxiliary proteins were detected by Western blotting using specific antibodies at the 
dilutions listed in Supplemental Table 1. 
 
Figure 8: Body weight and appearance of wildtype and slc6a19 nullizygous mice 
Appearance of male (54 days old) (A) and female (79 days old) (C) wildtype and Slc6a19 nullizygous 
mice. The body weight of male (B) and female (D) mice from mixed Slc6a19 wildtype (+/+), 
heterozygous (+/-) and nullizygous (-/-) litters was measured over a period of 84 days. Genotypes 
were determined after weaning on day 22. Before day 22 the average body weight of all three 
genotypes is depicted.  
 
Figure 9: Body weight changes in response to different diets. 
Wildtype (+/+) and Slc6a19 nullizygous (-/-) mice were fed isocaloric diets with protein contents of 
6%, 20% and 40%. The 20% protein diet corresponds to standard mouse chow, with which no body 
weight change was observed (not shown). (A) Body weight development on 6% protein diet. (B) 
Correlation between weight loss and absolute body weight on diets of different protein content in 
Slc6a19 nullizygous mice. Weight loss after 10 days is plotted against body weight at the start of the 
experiment. (C) Recovery of body weight development when Slc6a19 nullizygous mice were returned 
from a 6% protein diet to standard 20% protein diet. (D) Body weight development on a 40% diet. (E) 
Recovery of body weight development when Slc6a19 nullizygous mice were returned from a 40% 
protein diet to standard 20% protein diet. The weight traces were averaged and the mean ± SD for the 
indicated number of mice is depicted. Diets were used for 12 days before change to another diet. The 
inset shows the weight oscillation of an individual mouse between days 10 and day 50, which is not 
discernible in the averaged data. 
 
Figure 10: Analysis of body tissue composition. 
Mice body composition in wildtype (A) and Slc6a19 nullizygous mice (B) was analyzed using dual-
energy x-ray absorption (DEXA). Each data point presents an individual mouse and is the average of 
3 repeat measurements. The amount of fat and lean tissue is shown for each mouse on standard diet 
(20% protein) and after 10 days on diets of different protein content (6, 20 or 40%). The 
measurements on day 0 and day 10 are connected by lines.  
 
Figure 11: Amino acid signal transduction in the intestine 
Three sections of the small intestine (1cm each) were removed from wildtype and Slc6a19 
nullizygous mice, combined and homogenised to generate one sample. Three parallel samples (100 µg 
protein each) were separated by SDS-PAGE and blotted onto nitrocellulose. Subsequently, key 
proteins of amino acid signaling pathways were detected by specific antibodies as listed in 
Supplemental Table 1. Bands were quantified by densitometry and normalised to the actin control as 
shown in the histograms. Black bars represent wildtype data and white bars represent Slc6a19 
nullizygous mouse data.  
 
Figure 12 Insulin response and expression of Slc6a19 mRNA in mouse pancreas 
(A) Wildtype (black boxes) and Slc6a19 nullizygous animals (white boxes) were fasted for 16 h. 
Before refeeding a blood sample was taken and blood glucose and insulin levels were determined. 
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One hour after refeeding a second blood sample was taken and analyzed for glucose and insulin. The 
number of animals used is indicated. (B) Mouse pancreas was rapidly isolated and total RNA used to 
detect transcription of Slc6a19 and actin with specific primers in wildtype (+/+) and Slc6a19 
nullizygous mice (-/-). A reaction without added RNA (H2O) was used as a control. 
 
Figure 13 Overview of amino acid transport in intestine and kidney.  
Emphasis is given to processes affected by deletion of Slc6a19 as discussed in the text. 
Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9
Fig. 10
Fig. 11
Fig. 12
Fig. 13
